The FDA has started a review of Unicycive Therapeutics' drug for hyperphosphataemia in patients with chronic kidney disease ...

The integration of AI into drug submission and approval processes signifies a shift towards more efficient pharmaceutical ...

If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...

Autolus has picked up its first product approval, getting an FDA green light for Aucatzyl as a treatment for patients with ...

This 18th-20th February, 2025, London will host the premier HR event for European Life Sciences. Join CHROs, CPOs, and HR ...

Recent funding rounds in the digital health arena feature digital pathology startup Aignostics, remote care specialists TCC, ...

Researchers in the US have developed an artificial intelligence algorithm that can sift through electronic health records ...

As the reality of Donald Trump's victory in the US election starts to sink in, there are concerns about the future of the Affordable Care Act, which provides health insurance for more than 21 million ...

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

That is the conclusion of the much-anticipated Sudlow Review – carried out by Professor Cathie Sudlow, chief scientist of ...

For over 30 years, the US has clung to an outdated and misguided war on testosterone, lumping it in with the anabolic ...

CD40 agonists have had mixed results in cancer to date, with Roche discontinuing its selicrelumab candidate after ...